Stevens Capital Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Stevens Capital Management’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-34,075	Closed	-$402K	–	1158
2017 Q3	$402K	Sell	34,075 -26,392	-44%	-$296K	0.02%	607
2017 Q2	$635K	Buy	60,467 +46,657	+338%	+$476K	0.02%	523
2017 Q1	$152K	Buy	+13,810	New	+$160K	0.01%	795
2014 Q2	–	Sell	-17,251	Closed	-$123K	–	1428
2014 Q1	$123K	Buy	+17,251	New	+$148K	﹤0.01%	992
2013 Q4	–	Sell	-13,130	Closed	-$82K	–	1353
2013 Q3	$82K	Buy	+13,130	New	+$82K	﹤0.01%	978

Other funds holding SCMP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Stevens Capital Management's SCMP Position: Q4 2017 in Review

Stevens Capital Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2017, closing a stake of 34,075 shares — an estimated $402K sold.

Stevens Capital Management first reported a position in SCMP in Q3 2013 and held it in 5 quarters. The position peaked at $635K in Q2 2017. 188 funds tracked by Wall St. Rank hold SCMP as of Q4 2017.

Stevens Capital Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Stevens Capital Management sold 34,075 Sucampo Pharmaceuticals, Inc. shares in Q4 2017, an estimated $402K.
Stevens Capital Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q3 2013 and held it in 5 quarters.
Stevens Capital Management's Sucampo Pharmaceuticals, Inc. position peaked at $635K in Q2 2017.
188 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2017.

Based on Stevens Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.